Avadel Pharmaceuticals PLC
NASDAQ:AVDL
Avadel Pharmaceuticals PLC
EPS (Diluted)
Avadel Pharmaceuticals PLC
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
EPS (Diluted)
$0
|
CAGR 3-Years
27%
|
CAGR 5-Years
11%
|
CAGR 10-Years
15%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
EPS (Diluted)
-$1
|
CAGR 3-Years
-35%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
EPS (Diluted)
$8
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
27%
|
|
|
Iterum Therapeutics PLC
NASDAQ:ITRM
|
EPS (Diluted)
$0
|
CAGR 3-Years
52%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
EPS (Diluted)
$0
|
CAGR 3-Years
-53%
|
CAGR 5-Years
-137%
|
CAGR 10-Years
N/A
|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
EPS (Diluted)
€4
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-3%
|
|
Avadel Pharmaceuticals PLC
Glance View
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. The company is headquartered in Dublin, Dublin and currently employs 66 full-time employees. The Company’s lead product candidate, FT218, is an investigational once-nightly formulation of sodium oxybate for the treatment of excessive daytime sleepiness (EDS), and cataplexy in narcolepsy patients. Its Micropump allows for the development of modified and/or controlled release solid, oral dosage formulations of drugs. Its LiquiTime technology allows for development of modified/controlled release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its Medusa technology allows for the development of extended-/modified-release injectable dosage formulations of drugs.
See Also
What is Avadel Pharmaceuticals PLC's EPS (Diluted)?
EPS (Diluted)
-0.5
USD
Based on the financial report for Dec 31, 2024, Avadel Pharmaceuticals PLC's EPS (Diluted) amounts to -0.5 USD.
What is Avadel Pharmaceuticals PLC's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
15%
Over the last year, the EPS (Diluted) growth was 75%. The average annual EPS (Diluted) growth rates for Avadel Pharmaceuticals PLC have been 27% over the past three years , 11% over the past five years , and 15% over the past ten years .
You don't have any saved screeners yet